Institutions / ARCH Venture Management, LLC
ARCH Venture Management, LLC
CIK 1274403 · Institution · as of Mar 31, 2026
Portfolio value
$677.09M
Positions
10
As of
Mar 31, 2026
Portfolio trend
Portfolio value
$677.09M+3.9%Positions
10+11.1%Top holdings
Mar 31, 2026
| Company | Value | % of portfolio |
|---|---|---|
| Maze Therapeutics, Inc. | $122.98M | 18.2% |
| Rapport Therapeutics, Inc.RAPP | $116.67M | 17.2% |
| Vir Biotechnology, Inc. | $115.73M | 17.1% |
| Erasca, Inc.ERAS | $114.74M | 16.9% |
| Beam Therapeutics Inc. | $108.19M | 16.0% |
| Lyell Immunopharma, Inc.LYEL | $65.14M | 9.6% |
| Generate Biomedicines, Inc. | $24.31M | 3.6% |
| 10x Genomics, Inc. | $4.62M | 0.7% |
| Gossamer Bio, Inc. | $2.65M | 0.4% |
| Q32 Bio Inc. | $2.06M | 0.3% |
Activity
Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Trim | ERAS Erasca, Inc. Common Stock | $-64.14M | -4.0M -35.86% | 7,091,557 16.95% of portfolio | high |
| Q1 2026 as of | New | Generate Biomedicines, Inc. | $24.31M | +1.9M | 1,944,426 3.59% of portfolio | medium |
| Q1 2026 as of | Trim | 10x Genomics, Inc. | $-11.03M | -520K -70.46% | 217,834 0.68% of portfolio | medium |
| Q1 2026 as of | Add | LYEL Lyell Immunopharma, Inc. Common Stock | $9.79M | +488K +17.69% | 3,247,162 9.62% of portfolio | medium |